Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab for Peripheral Enthesitis in Spondyloarthropathies
NCT00686894Phase 4Terminated
- Sponsor
- Merck & Co.
- Start
- Jan 2008
- Primary completion
- Nov 2008
- Modality
- Monoclonal Antibodies
01
Overview
Phase 4, open-label, single-arm trial of infliximab in spondyloarthropathies (SpA) and ankylosing spondylitis (AS), sponsored by Merck & Co. Primary endpoint: Number of Enthesitis Evaluated Using Power Doppler Ultrasonography (PDUS) at 12 weeks. Started Jan 2008; status: terminated.
02
Drugs
infliximab
03
Conditions
spondyloarthropathies (SpA)ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT00686894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00686894.